Bayesian clinical trial design using historical data that inform the treatment effect.

We consider the problem of Bayesian sample size determination for a clinical trial in the presence of historical data that inform the treatment effect. Our broadly applicable, simulation-based methodology provides a framework for calibrating the informativeness of a prior while simultaneously identifying the minimum sample size required for a new trial such that the overall design has appropriate power to detect a non-null treatment effect and reasonable type I error control. We develop a comprehensive strategy for eliciting null and alternative sampling prior distributions which are used to define Bayesian generalizations of the traditional notions of type I error control and power. Bayesian type I error control requires that a weighted-average type I error rate not exceed a prespecified threshold. We develop a procedure for generating an appropriately sized Bayesian hypothesis test using a simple partial-borrowing power prior which summarizes the fraction of information borrowed from the historical trial. We present results from simulation studies that demonstrate that a hypothesis test procedure based on this simple power prior is as efficient as those based on more complicated meta-analytic priors, such as normalized power priors or robust mixture priors, when all are held to precise type I error control requirements. We demonstrate our methodology using a real data set to design a follow-up clinical trial with time-to-event endpoint for an investigational treatment in high-risk melanoma.

[1]  Ying Yuan,et al.  A Calibrated Power Prior Approach to Borrow Information from Historical Data with Application to Biosimilar Clinical Trials. , 2017, Journal of the Royal Statistical Society. Series C, Applied statistics.

[2]  A O'Hagan,et al.  Bayesian Assessment of Sample Size for Clinical Trials of Cost-Effectiveness , 2001, Medical decision making : an international journal of the Society for Medical Decision Making.

[3]  S J Pocock,et al.  The combination of randomized and historical controls in clinical trials. , 1976, Journal of chronic diseases.

[4]  Gene Pennello,et al.  Experience with Reviewing Bayesian Medical Device Trials , 2007, Journal of biopharmaceutical statistics.

[5]  Keying Ye,et al.  Evaluating water quality using power priors to incorporate historical information , 2006 .

[6]  J. Kirkwood,et al.  Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  D. Cox Regression Models and Life-Tables , 1972 .

[8]  Fei Wang,et al.  A simulation-based approach to Bayesian sample size determination for performance under a given model and for separating models , 2002 .

[9]  Anthony O'Hagan,et al.  Robust meta‐analytic‐predictive priors in clinical trials with historical control information , 2014, Biometrics.

[10]  Joseph G Ibrahim,et al.  Bayesian Design of Noninferiority Trials for Medical Devices Using Historical Data , 2011, Biometrics.

[11]  Joseph G Ibrahim,et al.  Bayesian design of superiority clinical trials for recurrent events data with applications to bleeding and transfusion events in myelodyplastic syndrome. , 2014, Biometrics.

[12]  E N Atkinson,et al.  Projection from previous studies: a Bayesian and frequentist compromise. , 1987, Controlled clinical trials.

[13]  SAMPLE SIZE DETERMINATION USING POSTERIOR PREDICTIVE DISTRIBUTIONS , 2016 .

[14]  Joseph G Ibrahim,et al.  Bayesian Meta‐Experimental Design: Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes , 2012, Biometrics.

[15]  Bradley P Carlin,et al.  Hierarchical Commensurate and Power Prior Models for Adaptive Incorporation of Historical Information in Clinical Trials , 2011, Biometrics.

[16]  J. Ibrahim,et al.  Power prior distributions for regression models , 2000 .

[17]  D. Spiegelhalter,et al.  A predictive approach to selecting the size of a clinical trial, based on subjective clinical opinion. , 1986, Statistics in medicine.

[18]  Joseph G Ibrahim,et al.  Bayesian sequential meta‐analysis design in evaluating cardiovascular risk in a new antidiabetic drug development program , 2014, Statistics in medicine.

[19]  Joseph G. Ibrahim,et al.  Bayesian Survival Analysis , 2004 .

[20]  Bradley P. Carlin,et al.  Bayesian measures of model complexity and fit , 2002 .